Innovation and Antibiotic Use within Antibiotic Classes: Market Incentives and Economic Instruments

Markus Herrmann (), Bruno Nkuiya () and Anne-Renée Dussault

Cahiers de recherche CREATE from CREATE

Abstract: We analyze a monopolist’s incentive to innovate a new antibiotic which is connected to the same pool of antibiotic treatment efficacy as is another drug produced by a generic industry. We outline the differences of antibiotic use under market conditions and in the social optimum. A time and state-dependent tax-subsidy mechanism is proposed to induce the monopolist and generic industry to exploit antibiotic efficacy optimally.

Keywords: Economics of antibiotic resistance; antibiotic innovation; monopoly; generic industry; social optimum; economic instruments (search for similar items in EconPapers)
JEL-codes: D21 D42 I18 Q38 (search for similar items in EconPapers)
Date: 2013
New Economics Papers: this item is included in nep-com, nep-hea and nep-ino
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.create.ulaval.ca/sites/create.ulaval.c ... ons/create2013-3.pdf (application/pdf)
Our link check indicates that this URL is bad, the error code is: 404 Not Found

Related works:
Journal Article: Innovation and antibiotic use within antibiotic classes: Market incentives and economic instruments (2013)
Working Paper: Innovation and Antibiotic Use within Antibiotic Classes: Market Incentives and Economic Instruments (2013)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:lvl:creacr:2013-3

Access Statistics for this paper

More papers in Cahiers de recherche CREATE from CREATE Contact information at EDIRC.
Bibliographic data for series maintained by Manuel Paradis ().